Search Blog
Categories
September 2019
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  

Tags

Vivera Pharmaceuticals’ Advisory Board Member Ron Brown Speaks Out About National Concussion Awareness Day

newsfilecorp

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6166/47942_6bb968a644b8eb6b_001.jpg

Newport Beach, California–(Newsfile Corp. – September 19, 2019) –

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6166/47942_6bb968a644b8eb6b_001full.jpg

About Vivera Pharmaceuticals, Inc.

Vivera Pharmaceuticals, Inc. is an innovative, science-driven pharmaceutical company focused on opioid deterrence and cessation and non-addictive solutions for pain management.

In addition to its pharmaceutical and medical device products, the company has global exclusivity to license the patented and patent-pending TABMELT™ sublingual drug-delivery system for the pharmaceutical use of cannabinoid compounds.

Vivera Pharmaceuticals is seeking to conduct case studies and clinical trials on CBD in the TABMELT™ drug delivery format with the goal of gaining FDA approval for its products.

The company is vertically integrated with patented technology, manufacturing capabilities and distribution for its products.

For more information, visit https://viverapharmaceuticals.com.

Investor Relations Inquiries:
thinkHERO
Patrick Piette, CFA for Vivera Pharmaceuticals, Inc.
416-526-9911
investorrelations@viverapharma.com

Press Inquiries:
thinkHERO
Karin Elz, for Vivera Pharmaceuticals, Inc.
416-992-9848
press@viverapharma.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/47942